Literature DB >> 21894147

Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model.

Shu-Chi Wang1, Ji-Hong Hong, Chuen Hsueh, Chi-Shiun Chiang.   

Abstract

A distinguishing feature of high-grade gliomas is the infiltration of neoplastic cells into adjacent brain tissues that mark most of these tumors surgically incurable. To study the factors associated with tumor invasion, we established a new murine brain tumor model, ALTS1C1 derived from SV40 large T antigen-transfected astrocytes. This new brain tumor model recapitulates several histopathological features of human high-grade glioma including increased cellularity, prominent cellular pleomorphism, geographic necrosis, active mitosis, and extensive invasion of tumor cells into adjacent brain tissues. More importantly, ALTS1C1 expressed a relatively high level of stromal-derived factor-1 (SDF-1/CXCL12) in vitro and in vivo and higher microvascular density (MVD) in vivo. To define the roles of SDF-1 in this tumor model, the expression of SDF-1 in ALTS1C1 cells was inhibited by specific siRNA. SDF-knockdown ALTS1C1 (SDF(kd)) cells took longer than parental ALTS1C1 cells to form tumors and in contrast to the wild-type tumors they had well-defined regular borders and lacked infiltration tracts. The SDF(kd) tumors were also associated with a lower MVD and more hypoxic areas. In contrast to parental tumors, the density of F4/80-positive tumor-associated macrophages (TAMs) in SDF(kd) tumor was higher in non-hypoxic than in hypoxic regions. SDF-1 production by tumor cells therefore seems critical for the aggregation of TAMs into areas of hypoxia and tumor invasiveness. This study not only provides new insight into the role of SDF-1 in brain tumor invasion and the relationship between TAMs and hypoxia, but also provides a new preclinical brain tumor model for designing new treatment options for invasive cases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21894147     DOI: 10.1038/labinvest.2011.128

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  73 in total

1.  Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.

Authors:  B R Achyut; Adarsh Shankar; A S M Iskander; Roxan Ara; Kartik Angara; Peng Zeng; Robert A Knight; Alfonso G Scicli; Ali S Arbab
Journal:  Cancer Lett       Date:  2015-09-21       Impact factor: 8.679

2.  Intravital 2-photon imaging reveals distinct morphology and infiltrative properties of glioblastoma-associated macrophages.

Authors:  Zhihong Chen; James L Ross; Dolores Hambardzumyan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 11.205

3.  An miR-340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of glioblastoma multiforme.

Authors:  Yunyun Liu; Xiaoyu Li; Yuanpei Zhang; Hongxuan Wang; Xiongming Rong; Jialing Peng; Lei He; Ying Peng
Journal:  Oncogene       Date:  2019-08-19       Impact factor: 9.867

Review 4.  Tumor-associated macrophages: role in cancer development and therapeutic implications.

Authors:  Arash Salmaninejad; Saeed Farajzadeh Valilou; Arash Soltani; Sepideh Ahmadi; Yousef Jafari Abarghan; Rhonda J Rosengren; Amirhossein Sahebkar
Journal:  Cell Oncol (Dordr)       Date:  2019-05-29       Impact factor: 6.730

Review 5.  The role of microglia and macrophages in glioma maintenance and progression.

Authors:  Dolores Hambardzumyan; David H Gutmann; Helmut Kettenmann
Journal:  Nat Neurosci       Date:  2016-01       Impact factor: 24.884

Review 6.  Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells.

Authors:  Nicole Colwell; Mioara Larion; Amber J Giles; Ashlee N Seldomridge; Saman Sizdahkhani; Mark R Gilbert; Deric M Park
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

Review 7.  Nanoparticles for Targeting Intratumoral Hypoxia: Exploiting a Potential Weakness of Glioblastoma.

Authors:  Mihaela Aldea; Ioan Alexandru Florian; Gabriel Kacso; Lucian Craciun; Sanda Boca; Olga Soritau; Ioan Stefan Florian
Journal:  Pharm Res       Date:  2016-05-26       Impact factor: 4.200

8.  Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.

Authors:  Ramon F Barajas; Bronwyn E Hamilton; Daniel Schwartz; Heather L McConnell; David R Pettersson; Andrea Horvath; Laszlo Szidonya; Csanad G Varallyay; Jenny Firkins; Jerry J Jaboin; Charlotte D Kubicky; Ahmed M Raslan; Aclan Dogan; Justin S Cetas; Jeremy Ciporen; Seunggu J Han; Prakash Ambady; Leslie L Muldoon; Randy Woltjer; William D Rooney; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

9.  Experimental and computational analyses reveal dynamics of tumor vessel cooption and optimal treatment strategies.

Authors:  Chrysovalantis Voutouri; Nathaniel D Kirkpatrick; Euiheon Chung; Fotios Mpekris; James W Baish; Lance L Munn; Dai Fukumura; Triantafyllos Stylianopoulos; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-30       Impact factor: 11.205

10.  S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages.

Authors:  Huaqing Wang; Leying Zhang; Ian Y Zhang; Xuebo Chen; Anna Da Fonseca; Shihua Wu; Hui Ren; Sam Badie; Sam Sadeghi; Mao Ouyang; Charles D Warden; Behnam Badie
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.